New Horizon Medical Solutions: Company Profile

Background

Overview

New Horizon Medical Solutions (NHMS) is a rapidly growing healthcare technology company specializing in biologics and advanced wound care solutions. The company offers an integrated model that combines high-quality regenerative products with comprehensive practice optimization systems, enabling healthcare providers to deliver improved patient outcomes while enhancing business operations.

Mission and Vision

NHMS is committed to transforming medical practices by elevating patient care and driving innovation. The company's mission is to provide trusted biologic products and end-to-end practice support that strengthen patient outcomes and financial performance. NHMS aims to empower healthcare providers with the tools and support necessary to deliver exceptional care while maintaining operational efficiency.

Primary Area of Focus

NHMS focuses on advanced wound care, offering a range of biologic products designed to accelerate healing and improve outcomes for both acute and chronic wounds. The company's portfolio includes skin substitutes, billing services, and practice optimization solutions tailored to the needs of healthcare providers.

Industry Significance

NHMS plays a significant role in the wound care industry by providing innovative biologic solutions that address the challenges of healing complex wounds. The company's integrated approach, combining high-quality products with operational support, positions it as a valuable partner for healthcare providers seeking to enhance patient care and practice efficiency.

Key Strategic Focus

Core Objectives

NHMS aims to:

Enhance patient outcomes through advanced wound care solutions.

Optimize healthcare providers' business operations.

Drive innovation in biologic products and practice management.

Specific Areas of Specialization

The company specializes in:

Development and distribution of biologic skin substitutes.

Comprehensive billing services tailored to medical specialties.

Practice optimization services, including workflow redesign and staff training.

Key Technologies Utilized

NHMS employs:

Amniotic membrane technology for regenerative wound care.

Advanced diagnostic imaging technologies, such as SnapshotNIR and SnapshotGLO.

Integrated practice management systems for operational efficiency.

Primary Markets Targeted

NHMS primarily serves:

Healthcare providers, including independent clinics and multispecialty groups.

Patients with acute and chronic wounds requiring advanced care.

Medical professionals seeking practice optimization and billing support.

Financials and Funding

Specific details regarding NHMS's funding history, total funds raised, recent funding rounds, and notable investors are not publicly disclosed. The company has demonstrated growth through strategic initiatives, including the expansion of its biologics portfolio and the establishment of manufacturing facilities. For instance, in September 2025, NHMS's subsidiary, Precision Biologics Manufacturing, broke ground on a new GMP-compliant facility in Las Vegas, Nevada, aiming to create 200–300 healthcare-centric jobs and expand U.S.-based biologics production.

Pipeline Development

Key Pipeline Candidates

NHMS's pipeline includes:

AdvoGraft™ One and AdvoGraft Membrane Dual: Biologic wound care products supporting natural healing for acute and chronic wounds. These products received CMS-approved Q codes, facilitating billing and reimbursement processes.

AmchoPlast™: A tri-layered amniotic membrane allograft designed to act as a barrier and provide protective coverage for various wound types.

Stages of Clinical Trials or Product Development

NHMS's products are in various stages of development, with some receiving regulatory approvals and others undergoing clinical validation. The company continues to expand its product offerings to address a broader range of wound care needs.

Target Conditions

NHMS's products target conditions such as:

Diabetic foot ulcers.

Venous leg ulcers.

Pressure ulcers.

Surgical wounds and dehiscence.

Trauma wounds and lacerations.

Post-Mohs surgical sites.

Graft donor sites and closures.

Relevant Timelines for Anticipated Milestones

NHMS has not publicly disclosed specific timelines for upcoming product milestones. The company continues to invest in research and development to bring innovative solutions to market.

Technological Platform and Innovation

Proprietary Technologies

NHMS's proprietary technologies include:

Amniotic Membrane Technology: Utilized in products like Xcell Amnio Matrix™ (XAM) and Xcellerate®, these biologic materials support wound healing by providing a scaffold for tissue regeneration.

Snapshot Suite: A partnership with Kent Imaging has enabled NHMS to offer advanced diagnostic imaging tools, including SnapshotNIR and SnapshotGLO, which assist clinicians in assessing tissue oxygenation and bacterial load in wounds.

Significant Scientific Methods

NHMS employs evidence-based design and precision manufacturing to develop its products, ensuring they meet the highest standards of safety and performance. The company also integrates advanced diagnostic imaging technologies to enhance clinical decision-making and improve patient outcomes.

AI-Driven Capabilities

While NHMS utilizes advanced technologies in its product offerings, specific AI-driven capabilities are not detailed in the available information.

Leadership Team

Key Executive Profiles

Will Hall: Chief Executive Officer (CEO)

Will Hall serves as the CEO of New Horizon Medical Solutions, leading the company's strategic direction and growth initiatives. Under his leadership, NHMS has expanded its biologics portfolio and established manufacturing facilities to enhance U.S.-based production.

D. Christopher Keil: Senior Vice President of Strategy and Corporate Development

D. Christopher Keil oversees strategic planning and corporate development at NHMS. He played a key role in the establishment of Precision Biologics Manufacturing, aiming to create 200–300 healthcare-centric jobs and expand U.S.-based biologics production.

Tharesh Udupa, DPM, FAPWHc, FAPWCA: Medical Director

Dr. Udupa co-leads NHMS's Medical Advisory Board, providing expertise in podiatry to guide the company's clinical strategy and product development.

Robert T. Grant, MD, MSc, FACS: Medical Director

Dr. Grant co-leads NHMS's Medical Advisory Board, offering expertise in plastic surgery to support a comprehensive approach to wound healing across care settings.

Leadership Changes

Recent significant changes include the establishment of the Medical Advisory Board in December 2025, co-led by Dr. Udupa and Dr. Grant, to advance evidence-based wound care innovation.

Competitor Profile

Market Insights and Dynamics

The wound care market is experiencing growth due to an aging population, increasing prevalence of chronic diseases, and advancements in biologic therapies. Healthcare providers are seeking innovative solutions to improve patient outcomes and operational efficiency.

Competitor Analysis

NHMS competes with other companies in the biologic wound care sector, such as:

Integra LifeSciences: Offers a range of regenerative tissue technologies for wound care.

Mölnlycke Health Care: Provides advanced wound care products and services.

Smith & Nephew: Offers biologic wound care solutions, including skin substitutes.

NHMS differentiates itself through its integrated approach, combining high-quality biologic products with comprehensive practice optimization services.